F
Francisco Sanchez-Vega
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 115
Citations - 20975
Francisco Sanchez-Vega is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 36, co-authored 84 publications receiving 13474 citations. Previous affiliations of Francisco Sanchez-Vega include Washington University in St. Louis & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
CpG island methylator phenotype in adenocarcinomas from the digestive tract: Methods, conclusions, and controversies
TL;DR: A data-driven, pan-gastrointestinal stratification of individual samples based on CIMP status is provided and correlations with oncogenic alterations, including somatic mutations and epigenetic silencing of tumor suppressor genes are investigated.
Journal ArticleDOI
Clinical and molecular features predicting long-term response (LTR) to anti-PD-(L)1 based therapy in patients with NSCLC.
Hira Rizvi,Andrew J. Plodkowski,Megan Tenet,Darragh Halpenny,Niamh Long,Jennifer L. Sauter,Francisco Sanchez-Vega,Walid K. Chatila,Nikolaus Schultz,Marc Ladanyi,Kathryn C. Arbour,Jamie E. Chaft,Matthew D. Hellmann +12 more
TL;DR: This data indicates that sustained response to anti-PD-(L)1 therapy is durable, long-term responses, which can last up to years, and this data bolsters the notion that this therapy is a “window of opportunity” for wound healing.
Journal ArticleDOI
Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma
Kyrollis Attalla,Renzo G. DiNatale,Phillip M Rappold,Christopher J. Fong,Francisco Sanchez-Vega,Andrew W. Silagy,Stanley Weng,Jonathan A. Coleman,Chung-Han Lee,Maria I. Carlo,Jeremy C. Durack,Stephen B. Solomon,Victor E. Reuter,Paul Russo,Timothy A. Chan,Robert J. Motzer,Nikolaus Schultz,Ed Reznik,Martin H. Voss,A. Ari Hakimi +19 more
TL;DR: In this paper, the authors report their experience with next-generation sequencing to characterize the landscape of actionable genomic alterations in renal cell carcinoma (RCC) and highlight the need for additional research to improve treatment selection using genomic profiling.
Journal ArticleDOI
Correlation of benefit from immune checkpoint inhibitors with next gen sequencing (NGS) profiles in esophagogastric cancer (EGC) patients.
Geoffrey Y. Ku,Francisco Sanchez-Vega,Walid K. Chatila,Matthew Margolis,Carly Fein,David H. Ilson,Jaclyn F. Hechtman,Yaelle Tuvy,Nancy Bouvier,Ritika Kundra,Jinru Shia,Zachary J. Heins,Sumit Middha,Ahmet Zehir,Marc Ladanyi,Michael F. Berger,Laura H. Tang,David B. Solit,Nikolaus Schultz,Yelena Y. Janjigian +19 more
TL;DR: Indo-oncology with anti-PD-1 and –PD-L1 antibodies is active in EGC but only benefits a minority of Pts, and biomarkers are needed to identify responders.
Journal ArticleDOI
Emergence of RTK/RAS/PI3K pathway alterations in trastuzumab-refractory HER2-positive esophagogastric (EG) tumors.
Yelena Y. Janjigian,Francisco Sanchez-Vega,Yaelle Tuvy,Nancy Bouvier,Jamie Riches,Matthew Margolis,Brittanie M Millang,Sasinya N. Scott,Ritika Kundra,Pau Castel,Geoffrey Y. Ku,Jaclyn F. Hechtman,David P. Kelsen,David H. Ilson,Efsevia Vakiani,Maurizio Scaltriti,David B. Solit,Barry S. Taylor,Michael F. Berger,Nikolaus Schultz +19 more
TL;DR: The once-weekly treatment of EG adenocarcinomas with trastuzumab with or without chemotherapy prolongs survival in patients with Stage IV HER2+ EG tumors is described.